Maureen Utz, MD
Dermatology · Excelsior, MNNPI 1609851229
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $426 of the $486 with a category attached, or 87.7%. It is spread thinly across 16 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $147 and has fallen 93.2% since, to $10 in 2025.
Across 30 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$79
- Incyte Corporation$67
- UCB, Inc.$62
- Tactile Systems Technology Inc$60
- Amgen$60
- Johnson & Johnson$34
- plus $124 from 10 others
What the payments were for
- Food & beverage$42688%
- Education$6012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 5 | $79 |
| Incyte Corporation | 4 | $67 |
| UCB, Inc. | 4 | $62 |
| Tactile Systems Technology Inc | 1 | $60 |
| Amgen | 4 | $60 |
| Johnson & Johnson | 2 | $34 |
| Sanofi | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
| Dermira, Inc. | 1 | $11 |
| Organon | 1 | $10 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $6 |
How this compares
$486 in reported general payments places this provider in the 65th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 70 | $5,164 |
| Metronidazole | 27 | $2,396 |
| Clobetasol Propionate | 41 | $1,943 |
| Ketoconazole | 42 | $1,011 |
| Tretinoin | 13 | $1,004 |
| Spironolactone | 19 | $556 |
| Triamcinolone Acetonide | 43 | $439 |
| Doxycycline Monohydrate | 18 | $292 |
| Econazole Nitrate | 12 | $238 |
| Mupirocin | 18 | $160 |
| ValacyclovirValacyclovir Hcl | 11 | $111 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Excelsior
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Todd SeelhammerSaint Paul$63K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
- Phillip EckerWayzata$31K
- Noah GoldfarbMinneapolis$30K
- Saranya WylesRochester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.